Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management
about
Herbal medicines for viral myocarditisHerbal medicines for viral myocarditisHerbal medicines for viral myocarditisCorticosteroids for viral myocarditisHerbal medicines for viral myocarditisCorticosteroids for viral myocarditisHerbal medicines for viral myocarditisImpact of cardiac magnetic resonance imaging in non-ischemic cardiomyopathiesPredictors of Extracorporeal Membrane Oxygenation Support for Children with Acute MyocarditisThe erythrocyte viral trap: transgenic expression of viral receptor on erythrocytes attenuates coxsackievirus B infectionIdentification and typing of human enterovirus: a genomic barcode approachPrevalence of human enteroviruses among apparently healthy nursery school children in Accra.High prevalence of human enterovirus a infections in natural circulation of human enteroviruses.Emerging therapeutic targets in nitric oxide-dependent cardiac disease.The failing heart: a bad case of the 'flu'.Acute actions and novel targets of matrix metalloproteinases in the heart and vasculatureRecent progress in understanding coxsackievirus replication, dissemination, and pathogenesis.Coxsackievirus-induced myocarditis: new trends in treatment.Silencing MicroRNA-155 Attenuates Cardiac Injury and Dysfunction in Viral Myocarditis via Promotion of M2 Phenotype Polarization of MacrophagesChildhood acquired heart diseases in Jos, north central NigeriaEffects of zileuton on the development of autoimmune myocarditis in an experimental rat model.Targeting matrix metalloproteinase activity and expression for the treatment of viral myocarditis.Inflammation and arrhythmias: potential mechanisms and clinical implications.Cardiac Autoimmunity: Myocarditis.MicroRNA-20b suppresses the expression of ZFP-148 in viral myocarditis.The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditisEffects of Shenqi Fuzheng injection on Fas/FasL protein expression levels in the cardiomyocytes of a mouse model of viral myocarditis.Myopericarditis: A Diagnosis of Uncertainty.Substance P receptor antagonism: a potential novel treatment option for viral-myocarditisInterferon-γ causes cardiac myocyte atrophy via selective degradation of myosin heavy chain in a model of chronic myocarditisMolecular analysis of enterovirus in Cameroon by partial 5'UTR-VP4 gene sequencing reveals a high genetic diversity and frequency of infections.Cleavage of osmosensitive transcriptional factor NFAT5 by Coxsackieviral protease 2A promotes viral replication.Cardiac findings in children with Crimean-Congo hemorrhagic fever.The cytotoxicity of coxsackievirus B3 is associated with a blockage of autophagic flux mediated by reduced syntaxin 17 expression.Thrombospondin-2 prevents cardiac injury and dysfunction in viral myocarditis through the activation of regulatory T-cells
P2860
Q24185801-9E28EB90-045C-4D47-97E4-D6FFD9435B7FQ24200215-49370445-DEDB-4CA2-93E4-45ED68E054B5Q24202848-9FA04F4A-684A-4D8F-A836-A004B8D21767Q24202995-EBA19814-DFE6-4C7A-AB00-0AE5A52C9729Q24234136-0A2139C2-F07C-4DB3-8ADA-37864BBA5770Q24243994-C67D699F-2199-40ED-8EFF-90AB3083412CQ24246795-6E8633EC-AF18-4CD1-9D17-3A3D7A8943DAQ26765173-8680EAA0-115F-4775-B209-DA36341F4B02Q33726293-7FE6E5E7-891E-422D-AF98-814E4B10D5AFQ33944023-3320025D-6137-4487-B8FF-CEFBE443A842Q34056244-3FAA250A-D56D-4CBD-8260-CAFA6237654DQ34502346-312365A8-3B26-4B44-A56E-E6F8B190A0D8Q34561950-001802D6-6DC3-441D-BAA1-2522D8FC547BQ35050418-3478B27B-DBF3-48B6-93D6-06941863E582Q35089179-8066CE02-9264-417D-BC6C-4EE5A95CBAB6Q35995215-75721809-2196-4AF8-B81C-43F14B9DC31FQ36052773-657CAE6A-6DFC-4602-9906-0855A68B229CQ36233532-597EB29D-0631-4DF9-91E9-B513D61F32B9Q36638515-80C94F0E-3C8C-4E23-8B1E-61E262058CA5Q36817695-A3021A0F-7B63-4994-8057-2CA29E734C39Q37667456-F0CF3EE3-ECF3-4E6B-A2CA-554962C621A1Q38174997-D33B0E1B-BC30-46FC-943E-9CB6E6EBEB67Q38233801-E95132D2-E46A-4D1D-8311-D6F5A8439784Q40138726-631FB110-9024-479E-825A-B021F30D54A2Q40313655-1C6CEFAE-78EB-45F1-B175-1F9ADDA8EA5BQ40410470-849AADC5-C70E-4FF0-850B-27D523A892D5Q40484694-294D9D2D-191F-4EB2-B5F7-D7A3665139F9Q40975377-C5EEE129-DA51-429B-BF57-667E01178E87Q41371705-989DE7CA-A83B-40C6-B90E-0B9DC3FEDE45Q42109729-93D4CB04-99B5-4303-83DD-F3B01A22C6D8Q42223739-F0893572-689B-4A50-8CBC-3563377D78ECQ47315412-EC49A055-3D2D-4BB2-962E-7F465D3CAB50Q49790537-5EB73DB0-7230-4269-AD04-1ED5F3A39DC5Q52694954-6CF96B79-D435-40DD-A066-60B506F6D9A2Q56898176-357BEA51-766C-42A2-8C72-BCCEA2592892
P2860
Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management
@ast
Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management
@en
Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management
@nl
type
label
Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management
@ast
Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management
@en
Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management
@nl
prefLabel
Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management
@ast
Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management
@en
Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management
@nl
P2093
P2860
P356
P1476
Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management
@en
P2093
J M Cotton
P J Richardson
P2860
P356
10.1136/PMJ.77.903.4
P407
P50
P577
2001-01-01T00:00:00Z